The North America Smart Inhalers Market is expected to witness market growth of 23.3% CAGR during the forecast period (2021 2027).
The growth in air pollution generated by naturally occurring phenomena as well as pollution-induced by manmade sources is a major factor contributing to the rise in COPD and asthma prevalence. Ozone, which is found in smog, and particulate matter, which is found in smoke, haze, and dust, are two major air pollutants that aggravate asthma. As the amount of ozone and particle matter in the air rises, the likelihood of developing asthma symptoms rises at an alarming rate. As a result, an increase in air pollution is predicted to directly contribute to a spike in asthma and COPD cases, propelling the market forward.
More technological capabilities are being introduced to smart inhalers on a daily basis, offering better and more comprehensive asthma management. Asthma patients will benefit from smart inhalers because these inhalers will make asthma management easier. They're primarily designed to lower the chances of poor asthma control and inappropriate therapy on a daily basis.
Due to factors such as increased digitalization in the healthcare sector, favorable government policies, and a flexible regulatory environment, the United States is expected to see profitable growth. Furthermore, rising private and public financing for smart inhalers will help the region grow even faster throughout the predicted period. As a result, such elements are to blame for the market's good expansion in North America. In the United States, rapid adoption of cutting-edge technology and the introduction of new end-user goods are likely to dominate market demand. Following the United States, Canada is represented in the market's top dominant shares. Growing government backing through health-sector investments, as well as improved treatment procedures, outnumbers the industry's demand for smart inhalers.
The US market dominated the North America Smart Inhalers Market by Country in 2020, and is expected to continue to be a dominant market till 2027; thereby, achieving a market value of $109,928.5 Thousands by 2027. The Canada market is estimated to grow at a CAGR of 26.1% during (2021 - 2027). Additionally, The Mexico market is expected to display a CAGR of 25% during (2021 - 2027).
Based on Product, the market is segmented into Metered Dose Inhalers (MDI's), and Dry Powdered Inhalers (DPIs). Based on Disease Indication, the market is segmented into Asthma, and Chronic Obstructive Pulmonary Disease (COPD). Based on Distribution Channel, the market is segmented into Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Adherium Limited, Aptar Group Inc. (Cohero Health Inc.), AstraZeneca, Inc., Cognita Labs, LLC, GlaxoSmithKline Plc, Novartis AG, OPKO Health, Inc., Philip Morris International, Inc. (Vectura Group Plc), Resmed, Inc. (Propeller Health), and Teva Pharmaceutical Industries Ltd.
The growth in air pollution generated by naturally occurring phenomena as well as pollution-induced by manmade sources is a major factor contributing to the rise in COPD and asthma prevalence. Ozone, which is found in smog, and particulate matter, which is found in smoke, haze, and dust, are two major air pollutants that aggravate asthma. As the amount of ozone and particle matter in the air rises, the likelihood of developing asthma symptoms rises at an alarming rate. As a result, an increase in air pollution is predicted to directly contribute to a spike in asthma and COPD cases, propelling the market forward.
More technological capabilities are being introduced to smart inhalers on a daily basis, offering better and more comprehensive asthma management. Asthma patients will benefit from smart inhalers because these inhalers will make asthma management easier. They're primarily designed to lower the chances of poor asthma control and inappropriate therapy on a daily basis.
Due to factors such as increased digitalization in the healthcare sector, favorable government policies, and a flexible regulatory environment, the United States is expected to see profitable growth. Furthermore, rising private and public financing for smart inhalers will help the region grow even faster throughout the predicted period. As a result, such elements are to blame for the market's good expansion in North America. In the United States, rapid adoption of cutting-edge technology and the introduction of new end-user goods are likely to dominate market demand. Following the United States, Canada is represented in the market's top dominant shares. Growing government backing through health-sector investments, as well as improved treatment procedures, outnumbers the industry's demand for smart inhalers.
The US market dominated the North America Smart Inhalers Market by Country in 2020, and is expected to continue to be a dominant market till 2027; thereby, achieving a market value of $109,928.5 Thousands by 2027. The Canada market is estimated to grow at a CAGR of 26.1% during (2021 - 2027). Additionally, The Mexico market is expected to display a CAGR of 25% during (2021 - 2027).
Based on Product, the market is segmented into Metered Dose Inhalers (MDI's), and Dry Powdered Inhalers (DPIs). Based on Disease Indication, the market is segmented into Asthma, and Chronic Obstructive Pulmonary Disease (COPD). Based on Distribution Channel, the market is segmented into Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Adherium Limited, Aptar Group Inc. (Cohero Health Inc.), AstraZeneca, Inc., Cognita Labs, LLC, GlaxoSmithKline Plc, Novartis AG, OPKO Health, Inc., Philip Morris International, Inc. (Vectura Group Plc), Resmed, Inc. (Propeller Health), and Teva Pharmaceutical Industries Ltd.
Scope of the Study
Market Segments Covered in the Report:
By Product
- Metered Dose Inhalers (MDI's)
- Dry Powdered Inhalers (DPIs)
By Disease Indication
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
By Distribution Channel
- Hospitals Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Adherium Limited
- Aptar Group Inc. (Cohero Health Inc.)
- AstraZeneca, Inc.
- Cognita Labs, LLC
- GlaxoSmithKline Plc
- Novartis AG
- OPKO Health, Inc.
- Philip Morris International, Inc. (Vectura Group Plc)
- Resmed, Inc. (Propeller Health)
- Teva Pharmaceutical Industries Ltd.
Unique Offerings from the publisher
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Competition Analysis - Global
Chapter 4. North America Smart Inhalers Market by Product
Chapter 5. North America Smart Inhalers Market by Disease Indication
Chapter 6. North America Smart Inhalers Market by Distribution Channel
Chapter 7. North America Smart Inhalers Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Adherium Limited
- Aptar Group Inc. (Cohero Health Inc.)
- AstraZeneca, Inc.
- Cognita Labs, LLC
- GlaxoSmithKline Plc
- Novartis AG
- OPKO Health, Inc.
- Philip Morris International, Inc. (Vectura Group Plc)
- Resmed, Inc. (Propeller Health)
- Teva Pharmaceutical Industries Ltd.
Methodology
LOADING...
